Chicago Atlantic Real Estate Finance Earnings Call Transcripts
Fiscal Year 2026
-
A merger between two complementary lending platforms will create a larger, more diversified entity focused on cannabis and middle market lending. The all-stock deal, expected to close in Q4 2026, aims to unlock value, improve access to capital, and enhance operational efficiency.
-
Stable Q1 2026 results with $13.1M net interest income and a $414M loan portfolio, despite macro volatility. Federal rescheduling of medical marijuana is expected to improve borrower credit profiles, while risk ratings and CECL reserves increased due to specific loans.
Fiscal Year 2025
-
Loan portfolio reached $411M with a 16.3% yield, net interest income rose 4% sequentially, and the pipeline expanded to $616M. Regulatory rescheduling is driving demand but not competition, and portfolio risk is well-managed with strong rate protections.
-
Consistent execution led to strong Q3 results, with a $400M portfolio, robust pipeline, and disciplined risk management. Net interest income and distributable earnings dipped slightly, but the portfolio remains well-insulated from rate declines.
-
Loan portfolio grew to $421.9M with a 16.8% yield, and net interest income rose 10.6% sequentially, driven by non-recurring fees and new deployments. Liquidity increased to $94M, and the credit facility was extended to 2028. Dividend payout ratio guidance remains at 90%-100%.
-
Q1 2025 saw limited new originations due to selectivity and industry caution, but a robust $462 million pipeline supports expectations for portfolio growth in 2025. Net interest income declined 7.3% sequentially, while credit quality and liquidity remain strong.
Fiscal Year 2024
-
Q4 results showed strong loan originations, robust credit quality, and a 6.7% stock price increase despite industry headwinds. Dividend payout remained high, leverage increased moderately, and the company maintained a conservative approach to regulatory risk.
-
Q3 2024 saw higher net interest income, improved credit quality, and a robust $560M investment pipeline. Portfolio risk was reduced by shifting to more fixed-rate loans, and leverage declined. Guidance was affirmed, with continued focus on top operators in key state markets.
-
Maintained a conservative portfolio approach amid regulatory uncertainty, with a $383 million loan portfolio and $13.2 million net interest income for Q2. Industry optimism is rising due to potential federal and state-level cannabis reforms, with strong growth prospects in Ohio and Florida.